Skip Navigation

Mark A. Velleca, M.D., Ph.D.

Valleca square 300x265

CEO, StrideBio

Dr. Mark Velleca serves as Chairman of the Board of Black Diamond Therapeutics. He is currently the CEO of StrideBio, a gene therapy company. Mark served as CEO of G1 Therapeutics (GTHX) until 2021, where he took the company public and led the development of its first therapy (COSELA®) from IND filing to FDA approval. He continues as a Senior Advisor to and board member of GTHX. Previously, Mark was Executive Vice President at the Leukemia & Lymphoma Society (LLS). Prior to LLS, Mark was a co-founder and Senior Vice President of CGI Pharmaceuticals, where he managed the company from its inception through clinical trials of multiple drug candidates. After Gilead Sciences acquired CGI, he served as a Senior Advisor to Gilead in R&D Strategy and Corporate Development.

Earlier in his career, Mark was an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine. Mark earned an M.D. and Ph.D. from Washington University in St. Louis, and a B.S. from Yale University.